Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094984 | 0.92 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL2141676 | 0.89 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL25215663 | 0.87 | HTT (0.46) | ALDH1A1L3MBTL1MAPK1SYKLTA4H | |
| SCHEMBL2139455 | 0.87 | LTA4H (0.48) | ALDH1A1L3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL7441838 | 0.86 | LTA4H (0.52) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL25196389 | 0.85 | SYK (0.45) | CA1CA2MEN1KMT2ASYK | |
| SCHEMBL6046926 | 0.84 | SYK (0.54) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL7332893 | 0.84 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL3294934 | 0.83 | LTA4H (0.57) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL11307178 | 0.83 | LTA4H (0.57) | ALDH1A1L3MBTL1MAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4440702-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | ALDH1A1 634/4885L3MBTL1 2573/4885MAPK1 4777/4885 |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | ALDH1A1 3774/4885L3MBTL1 4826/4885MAPK1 89/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | ALDH1A1 4511/4885L3MBTL1 2330/4885MAPK1 1591/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | ALDH1A1 1730/4885L3MBTL1 1651/4885MAPK1 1566/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885L3MBTL1 1204/4885MAPK1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.